A New Hope in Alzheimer's Treatment; Lecanemab
International Neuropsychiatric Disease Journal, Volume 19, Issue 1,
Lecanemab's apparent effectiveness follows years of disillusionment with earlier, comparable medications that were meant to delay or stop the course of Alzheimer's disease. It contains monoclonal antibodies that were created in laboratories with the goal of purging the brain of a material called as beta-amyloid, exactly like a lot of those other medicines. People with Alzheimer's disease tend to have an accumulation of beta-amyloid in their brains, which leads to the development of the sticky plaques that have come to be associated with the condition. As a result of this, the objective of his research paper is to investigate background information about the drug lecanemab. In addition to this, the study offers information regarding the approval procedure for lecanemab, the drug's mode of action, and, lastly, the most recent discoveries.
- monoclonal antibodies
- drug target
How to Cite
Landry I, Kanekiyo M, Aluri J, Li D, Hussein Z, Reyderman L, Kramer LD. Lecanemab (Ban2401) infusion reactions and immunogenicity: Results from randomized phase 2 study and an open-label extension; 2022.
Rawal S, Duong A, Landry I, Aluri J, Boyd P, Yagi T, Reyderman L. Absolute bioavailability of a single, fixed subcutaneous dose of lecanemab in healthy subjects. In Alzheimer's Association International Conference. ALZ; 2022.
Mahase E. Lecanemab trial finds slight slowing of cognitive decline, but clinical benefits are uncertain; 2022.
Reyderman L, Hayato S, Reddy H, Takenaka O, Yasuda S, Swanson CJ, Hussein Z. Modeled impact of APOE4 genotype on ARIA-E incidence in patients treated with lecanemab. In Alzheimer's Association International Conference. ALZ; 2022.
Samson K. Second amyloid antibody data rollout begins for alzheimer's disease: Is this aducanumab 2.0?. Neurology Today. 2021;21(21):1-15.
Shi M, Chu F, Zhu F, Zhu J. Impact of anti-amyloid-β monoclonal antibodies on the pathology and clinical profile of alzheimer’s disease: A focus on aducanumab and lecanemab. Frontiers in Aging Neuroscience; 2022;14.
TahamiMonfared AA, Tafazzoli A, Chavan A, Ye W, Zhang Q. The potential economic value of lecanemab in patients with early Alzheimer’s disease using simulation modeling. Neurology and Therapy. 2022;11(3):1285-1307.
Collins TR. Neurologists react to lecanemab news with swirl of excitement, Caution. Neurology Today. 2022;22(21):5-6.
Hayato S, Takenaka O, Sreerama Reddy SH, Landry I, Reyderman L, Koyama A, Hussein Z. Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease. CPT: Pharmacometrics & Systems Pharmacology; 2022.
Swanson CJ, Dhadda S, Irizarry MC, Kanekiyo M, Li DJ, Kaplow J, Kramer LD. Preliminary assessment of the clinical effects of lecanemab following 18 months of treatment in the open label extension of the phase 2 proof of concept study, BAN2401-G000-201, in subjects with early Alzheimer’s disease. In 2021 Alzheimer's Association International Conference. ALZ; 2021.
Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RY, Cummings JL. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimer's Research & Therapy. 2021;13(1):1-14.
Swanson CJ, Kanekiyo M, Kaplow J, Dhadda S, Irizarry M, Koyama A, Kramer LD. Extension Of The Phase 2 Proof-Of-Concept Study BAN2401-G000-201 Following treatment with lecanemab in subjects with early alzheimer’s disease; 2022.
Swanson CJ, Kanekiyo M, Kaplow J, Dhadda S, Irizarry MC, Koyama A, Kramer LD. Plasma Aβ 42:40 ratio tracks with changes in brain amyloid PET SUVr in the core and open label extension of the phase 2 proof of concept study ban2401‐g000‐201 following treatment with lecanemab in subjects with early Alzheimer’s disease. Alzheimer's & Dementia. 2021;17: e057760.
Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RY, Cummings JL. Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimer's Research & Therapy. 2022;14.
van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Iwatsubo T. Lecanemab in early Alzheimer’s disease. New England Journal of Medicine; 2022.
Tahami Monfared AA, Tafazzoli A, Ye W, Chavan A, Zhang Q. Long-term health outcomes of lecanemab in patients with early alzheimer's disease using simulation modeling. Neurol Ther. 2022;11(2):863-880. Epub 2022 Apr PMID: 35469060; PMCID: PMC9095799. DOI: 10.1007/s40120-022-00350-y
McDade E, Cummings JL, Dhadda S, Swanson CJ, Reyderman L, Kanekiyo M, Koyama A, Irizarry M, Kramer LD, Bateman RJ. Lecanemab in patients with early Alzheimer's disease: Detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimers Res Ther. 2022; 14(1):191. PMID: 36544184; PMCID: PMC9768996. DOI:10.1186/s13195-022-01124-2
Abstract View: 38 times
PDF Download: 26 times